MDT-AP-1191
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 9
- os_event
- false
- age_years
- 35
- sex
- F
- new_clusters
- S1
- umap1_2d
- 0.14858952
- umap2_2d
- -11.34157013
- umap1_3d
- -3.868411217
- umap2_3d
- 0.139215648
- umap3_3d
- 6.665646109
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.430
- MITOTIC_SPINDLE+0.320
- MYC_TARGETS_V2+0.270
- MTORC1_SIGNALING+0.170
- MYC_TARGETS_V1+0.150
- BILE_ACID_METABOLISM+0.100
- SPERMATOGENESIS+0.080
- PI3K_AKT_MTOR_SIGNALING+0.070
- UNFOLDED_PROTEIN_RESPONSE+0.070
Top 10 suppressed
- ANGIOGENESIS-0.390
- INFLAMMATORY_RESPONSE-0.340
- OXIDATIVE_PHOSPHORYLATION-0.330
- ALLOGRAFT_REJECTION-0.320
- PANCREAS_BETA_CELLS-0.300
- MYOGENESIS-0.280
- IL2_STAT5_SIGNALING-0.240
- IL6_JAK_STAT3_SIGNALING-0.240
- COMPLEMENT-0.230
- KRAS_SIGNALING_UP-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.848 |
| 2 | MDT-AP-3203 | Med | Medulloblastoma | 0.848 |
| 3 | TCGA-43-6143-01A-11R-1820-07 | — | cohortMD1 | 0.845 |
| 4 | SRR17866833 | — | — | 0.841 |
| 5 | MDT-AP-0138 | Med | Medulloblastoma | 0.836 |
| 6 | SRR650141 | — | — | 0.835 |
| 7 | TCGA-91-6847-01A-11R-1949-07 | — | cohortMD1 | 0.834 |
| 8 | BS_S6S7SK3P | high-grade glioma | — | 0.829 |
| 9 | TCGA-E5-A4TZ-01A-11R-A31N-07 | — | — | 0.826 |
| 10 | MDT-AP-3254 | Med | Medulloblastoma | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.010 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |